CF is a genetic disease that may result in multiple systemic disorders and potentially fatal severe respiratory compromise.
Researchers did this study to review the CFTR modulators to provide otolaryngologists. These physicians frequently care for CF patients, a basic understanding of these drugs, and their CRS effects in patients with CF.
The clinically approved and available CFTR modulators and specific indications for their use are reviewed. Additionally, a systematic review of these therapies and their effects on CRS in CF was performed.
Four Food and Drug Administration approved CFTR modulators are available for patients with CF. Current drugs are approved for gating, residual function, or F508del mutations. Multiple reports describe CFTR modulators’ increase in transepithelial ion transport in nasal epithelial cultures; however, clinical studies regarding these modulators’ effects on sinonasal health are limited to 5 pieces present new data on the impact of CFTR modulators in CRS.
CFTR modulators have changed the management of CF. Initial studies of these medications demonstrate promising results in CF; however, there is a lack of literature describing CFTR modulators’ effect on CF-associated CRS, although initial results are encouraging.